Xolair 300 MG/2 ML syringe 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FSKE8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,392
Award facts
- Contract value 100% obligated
- $11,392.44 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,392.44 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 mL syringes. This firm fixed-price delivery order, issued on December 2, 2025, with an ultimate completion date of December 23, 2025, was not issued under a set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc. serves as a critical supplier within the federal pharmaceutical supply chain, specializing in distributing branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables to Department of Defense healthcare facilities.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) designated SPE2DR, which was awarded on November 13, 2025, under the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The underlying IDC carries a ceiling value of $499,999,999 and extends through December 31, 2036, positioning DMS Pharmaceutical Group as one of multiple regional prime vendor contractors within the broader $30.3 billion PPV-G GEN V acquisition strategy. The contract authorizes DLA to issue firm fixed-price delivery orders for comprehensive pharmaceutical and medical consumable supplies to support recurring medical needs of military healthcare facilities worldwide, with DMS Pharmaceutical Group operating as a sole contractor on this award.
Quick answers
Who was awarded contract SPE2DR26FSKE8?
SPE2DR26FSKE8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 2, 2025.
How much is contract SPE2DR26FSKE8 worth?
The government has obligated $11,392 on SPE2DR26FSKE8.
Is contract SPE2DR26FSKE8 an order under another contract?
Yes. SPE2DR26FSKE8 is a delivery order under SPE2DR25D9317, an indefinite delivery contract.
Was contract SPE2DR26FSKE8 competed?
The extent of competition for SPE2DR26FSKE8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award